Literature DB >> 7904540

Alloreactive feature of HLA-DP-specific cytotoxic T-cell clone.

M Nishimura1, S Mitsunaga, T Akaza, Y Mitomi, K Tadokoro, T Juji.   

Abstract

The alloreactive feature of CD4+ cytotoxic T-cell clone that could specifically lyse the cells bearing DPB1*0202 sequence was described. The clone was generated from a mixed culture of peripheral blood lymphocytes derived from siblings who were HLA-A, B, C, DR, and DQ identical by serological typing and whose DNA sequence of the second exon of DPB1 was one-allele mismatched by oligonucleotide typing (responder, PDB1*0201/0402; stimulator, DPB1*0202/0402). Specific cytotoxic activity of the clone was strictly limited against the cells bearing DPB1*0202 and was not able to lyse the other tested cells bearing DPB1*0201, 0301, 0401, 0501, 0601, 0901, 1301, and 1601. The cytotoxic activity of the clone was blocked by treatment of target cells with anti-DP monoclonal antibodies (B7/21). On the other hand, treatment of target cells with blocking agents of endogenous or exogenous antigen transport pathway (brefeldin A (BFA), endogenous; chloroquine, exogenous) had no effect on the cytotoxic activity of the clone. These results strongly favor the view that the DP epitopes recognized by the clone are conformational epitopes conferred by specific amino acids in hypervariable regions of the HLA-DP second DPB1 exon and the contribution of peptides in the HLA grooves to the conformational epitope motif is less likely.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7904540     DOI: 10.1006/cimm.1994.1024

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  Human HLA-DR transgenes protect mice from fatal virus-induced encephalomyelitis and chronic demyelination.

Authors:  Moses Rodriguez; Laurie Zoecklein; Jason G Kerkvliet; Kevin D Pavelko; Louisa Papke; Charles L Howe; Larry R Pease; Chella David
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.